Cargando…

A multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge model

BACKGROUND: The purpose of this study was to evaluate the efficacy and duration of action of once-daily dosing with alcaftadine 0.25% ophthalmic solution and olopatadine 0.2% ophthalmic solution as compared with placebo in the prevention of ocular itching, and to directly compare the efficacy of alc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ackerman, Stacey, D’Ambrosio, Francis, Greiner, Jack V, Villanueva, Linda, Ciolino, Joseph B, Hollander, David A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3792834/ https://www.ncbi.nlm.nih.gov/pubmed/24109191 http://dx.doi.org/10.2147/JAA.S38671

Ejemplares similares

Ocular Itch Relief with Alcaftadine 0.25% Versus Olopatadine 0.2% in Allergic Conjunctivitis: Pooled Analysis of Two Multicenter Randomized Clinical Trials
por: McLaurin, Eugene B., et al.
Publicado: (2014)

Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis
por: Ayyappanavar, Shruti, et al.
Publicado: (2021)

Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%
por: Greiner, Jack V, et al.
Publicado: (2011)

Effect of alcaftadine 0.25% on ocular itch associated with seasonal or perennial allergic conjunctivitis: a pooled analysis of two multicenter randomized clinical trials
por: Ciolino, Joseph B, et al.
Publicado: (2015)

Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis
por: Dudeja, Lakshey, et al.
Publicado: (2019)

Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis
por: Ono, Santa J, et al.
Publicado: (2011)

Update and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis
por: Chigbu, DeGaulle I, et al.
Publicado: (2015)

364 Zero Itch in Eyes Treated With Olopatadine Hydrochloride Ophthalmic Solution, 0.2% in Bilateral Conjunctival Allergen Challenge Studies
por: Blaiss, Michael S., et al.
Publicado: (2012)

Allergic contact dermatitis of both eyes caused by alcaftadine 0.25%: a case report
por: Kim, Jae Hyuk, et al.
Publicado: (2019)

Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model
por: Torkildsen, Gail, et al.
Publicado: (2015)

Peculiar Properties of the La(0.25)Ba(0.25)Sr(0.5)Co(0.8)Fe(0.2)O(3−δ) Perovskite as Oxygen Reduction Electrocatalyst
por: Aliotta, Chiara, et al.
Publicado: (2023)

A Comparative Study of 0.25% Levobupivacaine, 0.25% Ropivacaine, and 0.25% Bupivacaine in Paediatric Single Shot Caudal Block
por: Sharma, Jagdeep, et al.
Publicado: (2018)

Projected 24-hour post-dose ocular itching scores post-treatment with olopatadine 0.7% versus 0.2%
por: Fidler, Matthew L., et al.
Publicado: (2018)

Evaluation of Photocatalytic Performance of Nano-Sized Sr(0.9)La(0.1)TiO(3) and Sr(0.25)Ca(0.25)Na(0.25)Pr(0.25)TiO(3) Ceramic Powders for Water Purification
por: Jovanoski Kostić, Aleksandra, et al.
Publicado: (2022)

Anti-Plaque and Anti-Gingivitis Efficacy of 0.25% Lemongrass Oil and 0.2% Chlorhexidine Mouthwash in Children
por: Akula, Sreekumar, et al.
Publicado: (2021)

A comparison of epidural infusion of 0.2, 0.25, and 0.3% ropivacaine with fentanyl after unilateral total knee arthroplasty
por: Lee, Jae Ho, et al.
Publicado: (2013)

Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies
por: Epstein, Arthur B, et al.
Publicado: (2009)

Efficacy of 0.05% epinastine and 0.1% olopatadine for allergic conjunctivitis as seasonal and preseasonal treatment
por: Mizoguchi, Takanori, et al.
Publicado: (2017)

Exchange-bias via nanosegregation in novel Fe(2−x)Mn(1+x)Al (x = −0.25, 0, 0.25) Heusler films
por: Kurdi, S., et al.
Publicado: (2020)

Potential outstanding physical properties of novel black arsenic phosphorus As(0.25)P(0.75)/As(0.75)P(0.25) phases: a first-principles investigation
por: Liu, Fangqi, et al.
Publicado: (2022)

Caudal Epidural Analgesia in Pediatric Patients: Comparison of 0.25% Levobupivacaine and 0.25% Ropivacaine in Terms of Motor Blockade and Postoperative Analgesia
por: Praveen, P., et al.
Publicado: (2017)

Hydrothermal Synthesis and Crystal Structure of a Novel Bismuth Oxide: (K(0.2)Sr(0.8))(Na(0.01)Ca(0.25)Bi(0.74))O(3)
por: Hossain, Khandaker Monower, et al.
Publicado: (2021)

Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness: A Randomized Clinical Trial
por: McLaurin, Eugene, et al.
Publicado: (2018)

Lotilaner Ophthalmic Solution 0.25%: First Approval
por: Syed, Yahiya Y.
Publicado: (2023)

Critical phenomena and estimation of the spontaneous magnetization from a mean field analysis of the magnetic entropy change in La(0.7)Ca(0.1)Pb(0.2)Mn(0.95)Al(0.025)Sn(0.025)O(3)
por: Dhahri, Khadija, et al.
Publicado: (2018)

A Comparative Study of Effect of 0.25% Levobupivacaine with Dexmedetomidine versus 0.25% Levobupivacaine in Ultrasound-Guided Supraclavicular Brachial Plexus Block
por: Iyer, Lakshmi S., et al.
Publicado: (2021)

Tin-Decorated Reduced Graphene Oxide and NaLi(0.2)Ni(0.25)Mn(0.75)O(δ) as Electrode Materials for Sodium-Ion Batteries
por: Prosini, Pier Paolo, et al.
Publicado: (2019)

Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference
por: McCabe, Craig F, et al.
Publicado: (2012)

KNb(1.75)V(0.25)PS(10)
por: Yu, Jaemin, et al.
Publicado: (2011)

Treatment of angiokeratomas of Fordyce with topical rapamycin 0.25% cream
por: Bell, Katheryn A., et al.
Publicado: (2020)

Correction to: Lotilaner Ophthalmic Solution 0.25%: First Approval
por: Syed, Yahiya Y.
Publicado: (2023)

A case report of allergic blepharoconjunctivis to alcaftadine
por: Sandrin, Leda Das Neves Almeida
Publicado: (2015)

Analogous Anti-Ferroelectricity in Y(2)O(3)-Coated (Pb(0.92)Sr(0.05)La(0.02))(Zr(0.7)Sn(0.25)Ti(0.05))O(3) Ceramics and Their Energy-Storage Performance
por: Fang, Bijun, et al.
Publicado: (2019)

Dynamic Mechanical Properties and Microstructure of an (Al(0.5)CoCrFeNi)(0.95)Mo(0.025)C(0.025) High Entropy Alloy
por: Wang, Bingfeng, et al.
Publicado: (2019)

1-Benzyl-3-methylimidazolium chloride 0.25-hydrate
por: Ji, Xiujie, et al.
Publicado: (2009)

Possible quadrupole-first options with $\beta^* \leq$ 0.25M
por: Koutchouk, Jean-Pierre
Publicado: (2006)

Standard of Spectral Radiance for the Region of 0.25 to 2.6 Microns
por: Stair, Ralph, et al.
Publicado: (1960)

Experiments on MEMS Integration in 0.25 μm CMOS Process
por: Michalik, Piotr, et al.
Publicado: (2018)

Cataract Surgery by Intraoperative Surface Irrigation with 0.25% Povidone–Iodine
por: Shimada, Hiroyuki, et al.
Publicado: (2021)

Nanostructured La(0.75)Sr(0.25)Cr(0.5)Mn(0.5)O(3)–Ce(0.8)Sm(0.2)O(2) Heterointerfaces as All-Ceramic Functional Layers for Solid Oxide Fuel Cell Applications
por: Sirvent, Juan de Dios, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ucn92934cehbnk9o3tdmr20l10